THE BUZ ON CANNABIS STOCK




Cannabis Stock 

CANNABIS BUZZ Pure play marijuana stocks are scarce. Most companies in the marijuana industry trade over the counter (OTC), where solid information regarding operations and financials is difficult to retrieve. Exceptions extend to issues such as GW Pharmaceuticals plc (NASDAQ: GWPH), a British biopharmaceutical company that developed two cannabis-based drugs licensed for use outside the United States. Sativex is used to treat muscular contractions in multiple sclerosis patients, and Epidiolex targets epileptic seizures in children. Both drugs have entered Phase 3 clinical stage trials in the United States. GWPH has a $2 billion market cap and had returned 23% year to date (YTD) as of Aug. 15, 2016.

Political and legal obstacles remain the highest hurdles for the marijuana industry in 2016. Four states, Oregon, Washington, Alaska and Colorado, have legalized recreational marijuana, and 25 states plus the District of Columbia have approved cannabis for medicinal purposes. The plant is categorized at the federal level as a Schedule 1 drug, possessing the highest risk for psychological and physical dependence, and more curiously, having no acceptable medical use.

BUZ INVESTORS PRESS RELEASE Scorpion Grow Lights Future Farm Technologies Inc. (the “Company” or “Future Farm”) ( OTCQB : FFRMF ) is pleased to announce that it is sold out of its exclusive line of Scorpion LED COB Grow Lights
CANNABIS BUZZ

Future Farm Sets Closing Date for RI Building Zoned for Cannabis

Future Farm Sets Closing Date for RI Building Zoned for Cannabis; Receives $1.4 Million in Warrant Conversions; and Provides Update on Voluntary Shareholder Warrant Conversion December 12, 2017 – Vancouver, British Columbia – Future Farm Technologies Inc. (the “Company” or “Future Farm”) (CSE: FFT) (OTCQB: FFRMF) is pleased to announce that the closing date for […]

Buz Investors CMED, receives export permits CanniMed Therapeutics Inc. (“CanniMed” or the “Company”) (TSX: CMED) today announced the receipt, through its wholly-owned subsidiary Prairie Plant Systems Inc., of
CANNABIS BUZZ PRESS RELEASES

CanniMed Commences Legal Action against the Aurora Hostile Bid

CanniMed Commences Legal Action against the Aurora Hostile Bid; Files Proxy and Directors’ Circulars; Urges Shareholders to Vote Their Green Proxy in Favour of the Newstrike Acquisition, and to Take No Action to Reject Aurora’s Hostile Bid – CanniMed has commenced legal action against Aurora for regulatory orders that, among other things, the Hostile Bid […]

BUZ INVESTORS PRESS RELEASE Debenture Offering Aurora Cannabis Inc. (the "Company" or "Aurora") (TSXV: ACB) (OTCQX: ACBFF) (
CANNABIS BUZZ PRESS RELEASES

Actions Versus Words: Aurora CEO’s Actions Reveal That Aurora Stock is Inflated; Insiders Sell $17 Million in Stock During Their Hostile Take-over Bid for CanniMed and During a Financing

Actions Versus Words: Aurora CEO’s Actions Reveal That Aurora Stock is Inflated; Insiders Sell $17 Million in Stock During Their Hostile Take-over Bid for CanniMed and During a Financing Despite trying to convince CanniMed shareholders to take Aurora’s shares in their opportunistic and coercive hostile bid, Aurora insiders’ cash out evidences their belief that Aurora’s […]

BUZ INVESTORS PRESS RELEASE Comprehensive Amendment Agreements Tauriga Sciences Inc. ( OTC PINK : (TAUG ) (“Tauriga” or “the Company”),
CANNABIS BUZZ PRESS RELEASES

Tauriga Sciences, Inc. Announces the Relocation of its Corporate Headquarters to Midtown Manhattan

Tauriga Sciences, Inc. Announces the Relocation of its Corporate Headquarters to Midtown Manhattan NEW YORK, NY–(Marketwired – Nov 29, 2017) – Tauriga Sciences, Inc. (OTC PINK: TAUG) (“Tauriga” or the “Company”) today announced that it has decided to move its corporate headquarters from Danbury, Connecticut to Midtown Manhattan in New York City. The effective date of this […]

BUZ INVESTORS Definitive Agreement Tetra Bio-Pharma Inc. (“Tetra” orCN)announced today
CANNABIS BUZZ PRESS RELEASES

Tetra Bio-Pharma accelerates submission of New Drug Application to FDA & Expects to Commercialize Dronabinol XL Tablet

Tetra Bio-Pharma accelerates submission of New Drug Application to FDA & Expects to Commercialize Dronabinol XL Tablet Ahead of Schedule(1) in the US   OTTAWA, ONTARIO–(Marketwired – Nov. 28, 2017) – Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX VENTURE:TBP) (OTCQB:TBPMF), a global leader in cannabinoid-based drug development, today announced that it is partnering with […]